These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 7286578)

  • 1. Normal metabolism of morphine in cirrhosis.
    Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
    Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis.
    Callaghan R; Desmond PV; Paull P; Mashford ML
    Hepatology; 1993 Jul; 18(1):54-60. PubMed ID: 8325621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT; Marigold JH; Thompson RP
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
    Saudek F; Morávek J; Modr Z
    Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temazepam clearance unaltered in cirrhosis.
    Ochs HR; Greenblatt DJ; Verburg-Ochs B; Matlis R
    Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
    Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
    Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
    Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis.
    Neal EA; Meffin PJ; Gregory PB; Blaschke TF
    Gastroenterology; 1979 Jul; 77(1):96-102. PubMed ID: 447033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colchicine clearance is impaired in alcoholic cirrhosis.
    Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
    Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolism of riboflavin in female patients with liver cirrhosis.
    Zempleni J; Galloway JR; McCormick DB
    Int J Vitam Nutr Res; 1996; 66(3):237-43. PubMed ID: 8899458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass].
    Bolognesi M; Merkel C; Angeli P; Caregaro L; Gatta A
    Minerva Med; 1988 Dec; 79(12):1035-41. PubMed ID: 3211355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipyrone metabolism in liver disease.
    Zylber-Katz E; Caraco Y; Granit L; Levy M
    Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyramine kinetics and metabolism in cirrhosis.
    Faraj BA; Fulenwider JT; Rypins EB; Nordlinger B; Ivey GL; Jansen RD; Ali FM; Camp VM; Kutner M; Schmidt F; Rudman D
    J Clin Invest; 1979 Aug; 64(2):413-20. PubMed ID: 457860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrahepatic glucuronidation of morphine in the dog.
    Jacqz E; Ward S; Johnson R; Schenker S; Gerkens J; Branch RA
    Drug Metab Dispos; 1986; 14(6):627-30. PubMed ID: 2877817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics.
    Birnie GG; Fitzsimons CP; Czarnecki D; Cooke A; Scobie G; Brodie MJ
    Hepatogastroenterology; 1985 Aug; 32(4):163-7. PubMed ID: 2865199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction.
    Marshall JP; Salt WB; Elam RO; Wilkinson GR; Schenker S
    Gastroenterology; 1977 Dec; 73(6):1388-92. PubMed ID: 913979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.